Patient perspectives on chronic rhinosinusitis in cystic fibrosis : Symptom prioritization in the era of highly effective modulator therapy
© 2024 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society..
BACKGROUND: Chronic rhinosinusitis (CRS) is common in people with cystic fibrosis (PwCF). Rhinologic symptom prioritization and areas that influence CRS treatment choices, including pursuing endoscopic sinus surgery (ESS), remain understudied.
METHODS: Adult PwCF + CRS were enrolled at eight centers into a prospective, observational study (2019-2023). Participants were administered the 22-SinoNasal Outcome Test (SNOT-22) survey and a modified SNOT-22 instrument examining symptom importance. We determined importance rankings for individual symptoms and SNOT-22 symptom importance subdomains in two sets of subgroups-those pursuing ESS versus continuing medical management (CMT), and those on elexacaftor/tezacaftor/ivacaftor (ETI) versus not on ETI.
RESULTS: Among 69 participants, the highest priorities were nasal congestion (n = 48, 69.6% important), post-nasal discharge (32, 46.4%), facial pain (29, 43.3%), waking up tired (27, 39.1%), and fatigue (26, 37.7%). Those electing surgery (n = 23) prioritized sleep and psychological dysfunction symptoms compared to those pursuing CMT (n = 49) (sleep median score = 19.0 [interquartile range: 12.0, 25.0] vs. 4.5 [0.0, 12.8]; p < 0.0001; psychological = 17.0 [7.0, 26.0] vs. 7.0 [0.0, 15.8]; p = 0.002). ETI users had comparable SNOT-22 total symptom importance scores to non-ETI users (p = 0.14). Non-ETI users (n = 34) showed a trend toward prioritizing sleep symptoms compared to ETI users (n = 35) (13.0 [2.8, 22.3] vs. 6.0 [2.0, 17.0]; p = 0.055).
CONCLUSIONS: Nasal congestion and post-nasal discharge were top priorities reported by PwCF + CRS. Those electing surgery prioritized sleep and psychological symptoms, highlighting their importance in pre-operative discussions. Non-ETI users' prioritization of sleep improvement may highlight their unique disease impact and therapeutic needs; however, additional investigation is required.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
International forum of allergy & rhinology - (2024) vom: 11. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Christine M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chronic rhinosinusitis |
|---|
| Anmerkungen: |
Date Revised 12.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1002/alr.23332 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368332926 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368332926 | ||
| 003 | DE-627 | ||
| 005 | 20240213233030.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240213s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/alr.23332 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1291.xml |
| 035 | |a (DE-627)NLM368332926 | ||
| 035 | |a (NLM)38343143 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Christine M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Patient perspectives on chronic rhinosinusitis in cystic fibrosis |b Symptom prioritization in the era of highly effective modulator therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society. | ||
| 520 | |a BACKGROUND: Chronic rhinosinusitis (CRS) is common in people with cystic fibrosis (PwCF). Rhinologic symptom prioritization and areas that influence CRS treatment choices, including pursuing endoscopic sinus surgery (ESS), remain understudied | ||
| 520 | |a METHODS: Adult PwCF + CRS were enrolled at eight centers into a prospective, observational study (2019-2023). Participants were administered the 22-SinoNasal Outcome Test (SNOT-22) survey and a modified SNOT-22 instrument examining symptom importance. We determined importance rankings for individual symptoms and SNOT-22 symptom importance subdomains in two sets of subgroups-those pursuing ESS versus continuing medical management (CMT), and those on elexacaftor/tezacaftor/ivacaftor (ETI) versus not on ETI | ||
| 520 | |a RESULTS: Among 69 participants, the highest priorities were nasal congestion (n = 48, 69.6% important), post-nasal discharge (32, 46.4%), facial pain (29, 43.3%), waking up tired (27, 39.1%), and fatigue (26, 37.7%). Those electing surgery (n = 23) prioritized sleep and psychological dysfunction symptoms compared to those pursuing CMT (n = 49) (sleep median score = 19.0 [interquartile range: 12.0, 25.0] vs. 4.5 [0.0, 12.8]; p < 0.0001; psychological = 17.0 [7.0, 26.0] vs. 7.0 [0.0, 15.8]; p = 0.002). ETI users had comparable SNOT-22 total symptom importance scores to non-ETI users (p = 0.14). Non-ETI users (n = 34) showed a trend toward prioritizing sleep symptoms compared to ETI users (n = 35) (13.0 [2.8, 22.3] vs. 6.0 [2.0, 17.0]; p = 0.055) | ||
| 520 | |a CONCLUSIONS: Nasal congestion and post-nasal discharge were top priorities reported by PwCF + CRS. Those electing surgery prioritized sleep and psychological symptoms, highlighting their importance in pre-operative discussions. Non-ETI users' prioritization of sleep improvement may highlight their unique disease impact and therapeutic needs; however, additional investigation is required | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a chronic rhinosinusitis | |
| 650 | 4 | |a cystic fibrosis | |
| 650 | 4 | |a endoscopic sinus surgery | |
| 650 | 4 | |a highly effective modulator therapy | |
| 650 | 4 | |a patient priorities | |
| 650 | 4 | |a patient symptoms | |
| 650 | 4 | |a symptom importance | |
| 700 | 1 | |a Han, Ethan J |e verfasserin |4 aut | |
| 700 | 1 | |a Fischer, Jakob L |e verfasserin |4 aut | |
| 700 | 1 | |a Mace, Jess C |e verfasserin |4 aut | |
| 700 | 1 | |a Mattos, Jose L |e verfasserin |4 aut | |
| 700 | 1 | |a Markarian, Karolin |e verfasserin |4 aut | |
| 700 | 1 | |a Alt, Jeremiah A |e verfasserin |4 aut | |
| 700 | 1 | |a Bodner, Todd E |e verfasserin |4 aut | |
| 700 | 1 | |a Chowdhury, Naweed I |e verfasserin |4 aut | |
| 700 | 1 | |a Eshaghian, Patricia H |e verfasserin |4 aut | |
| 700 | 1 | |a Getz, Anne E |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Peter H |e verfasserin |4 aut | |
| 700 | 1 | |a Khanwalkar, Ashoke |e verfasserin |4 aut | |
| 700 | 1 | |a Kimple, Adam J |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jivianne T |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Douglas A |e verfasserin |4 aut | |
| 700 | 1 | |a Norris, Meghan |e verfasserin |4 aut | |
| 700 | 1 | |a Nayak, Jayakar V |e verfasserin |4 aut | |
| 700 | 1 | |a Owens, Cameran |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Zara M |e verfasserin |4 aut | |
| 700 | 1 | |a Poch, Katie |e verfasserin |4 aut | |
| 700 | 1 | |a Schlosser, Rodney J |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kristine A |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Timothy L |e verfasserin |4 aut | |
| 700 | 1 | |a Soler, Zachary M |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Jeffrey D |e verfasserin |4 aut | |
| 700 | 1 | |a Turner, Grant A |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Marilene B |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor-Cousar, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Saavedra, Milene T |e verfasserin |4 aut | |
| 700 | 1 | |a Beswick, Daniel M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International forum of allergy & rhinology |d 2011 |g (2024) vom: 11. Feb. |w (DE-627)NLM209105178 |x 2042-6984 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:11 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/alr.23332 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 11 |c 02 | ||